Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vesatolimod - Gilead Sciences

Next Previous
Drug Profile

Vesatolimod - Gilead Sciences

Alternative Names: GS-9620

Latest Information Update: 09 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Aelix Therapeutics; Gilead Sciences; National Institute of Allergy and Infectious Diseases
  • Class Amines; Antiretrovirals; Antivirals; Ethers; Pteridines; Pyrrolidines; Small molecules
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 02 Sep 2026 National Institute of Allergy and Infectious Diseases in collaboration with Gilead Sciences suspends the phase-I/II trial in HIV-1 infections (Combination therapy, Treatment-experienced) in US and Brazil (NCT06071767)
  • 02 Jul 2025 National Institute of Allergy and Infectious Diseases in collaboration with Gilead Sciences re-initiated a phase I/II trial in HIV 1 infection (Combination therapy,Treatment-experienced) in US and Brazil (NCT06071767)
  • 25 Apr 2025 National Institute of Allergy and Infectious Diseases in collaboration with Gilead Sciences suspends a phase I/II trial in HIV 1 infection (Combination therapy,Treatment-experienced) in US and Brazil (NCT06071767)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top